WS Investor
16 Nov 2026, 16:42
Medtronic to Acquire Contego Medical for $380 Million to Expand Carotid Portfolio
Medtronic (NYSE: MDT) agreed to acquire privately held Contego Medical for $380 million, with additional potential post-acquisition payments.
The deal adds Contego’s FDA-approved Neuroguard IEP Direct System, a transcarotid artery revascularization platform with integrated embolic protection, along with Excipio thrombectomy devices for peripheral vascular disease.
Medtronic said the acquisition will strengthen its position in carotid artery disease and build on an exclusive U.S. distribution agreement with Contego that began in 2025.
The transaction is expected to close in Medtronic’s fiscal third quarter and is projected to be minimally dilutive to adjusted EPS in FY27 and FY28, becoming neutral to accretive thereafter.
Medtronic (NYSE: MDT) agreed to acquire privately held Contego Medical for $380 million, with additional potential post-acquisition payments.
The deal adds Contego’s FDA-approved Neuroguard IEP Direct System, a transcarotid artery revascularization platform with integrated embolic protection, along with Excipio thrombectomy devices for peripheral vascular disease.
Medtronic said the acquisition will strengthen its position in carotid artery disease and build on an exclusive U.S. distribution agreement with Contego that began in 2025.
The transaction is expected to close in Medtronic’s fiscal third quarter and is projected to be minimally dilutive to adjusted EPS in FY27 and FY28, becoming neutral to accretive thereafter.